DUBLIN--(BUSINESS WIRE)--Nov 5, 2019--

The Global Lymphedema Diagnostics Market is Projected to Reach USD 35 Million by 2024 from USD 24 Million in 2019, at a CAGR of 7.4%.

The major factors driving the growth of this market include the increasing global prevalence of cancer and lymphedema; technological advancements in diagnostic imaging modalities; and increasing investments, funds, and grants by public-private organizations. However, the high cost of diagnostic imaging systems, the short half-life of radiopharmaceuticals, and the limited supply of helium are expected to hinder the growth of this market.

The lymphoscintigraphy segment accounted for the largest market share in 2018.

Based on technology, the lymphedema diagnostics market is segmented into lymphoscintigraphy, magnetic resonance imaging (MRI), ultrasound imaging, computed tomography (CT), X-ray lymphography, bioimpedance analysis, and near-infrared fluorescence imaging. The lymphoscintigraphy segment accounted for the largest share of the lymphedema diagnostics market in 2018. The noninvasive nature and easy reproducibility of this technology, and the fact that lymphoscintigraphy does not adversely affect the lymphatic vascular endothelium are some of the key advantages supporting the adoption of this technology.

The cancer segment accounted for the largest share of the lymphedema diagnostics market in 2018.

On the basis of disease type, the lymphedema diagnostics market is segmented into cancer, inflammatory diseases, cardiovascular disease, and other diseases (congenital abnormalities, trauma-related conditions, infections, and filariasis). The cancer segment accounted for the largest share of the lymphedema diagnostics market in 2018. The large share of this segment can be attributed to the rising prevalence of cancer-associated lymphedema and increasing awareness about early disease diagnosis.

Europe to account for the second-largest share of the global market in 2019.

The lymphedema diagnostics market is segmented into four major regions, namely, North America, Europe, the Asia Pacific, and the Rest of the World. Europe is expected to account for the second-largest share of the global lymphedema diagnostics market in 2019. The rising incidence of chronic diseases and injuries, growing demand for early diagnosis and treatment, technological advancements, product launches, and increasing government and public-private investments for developing novel diagnostic imaging modalities are the major factors driving market growth in Europe.

Market Dynamics

Drivers

  • Growing Global Prevalence of Lymphedema
  • Growing Global Prevalence of Cancer
  • Technological Advancements and Adoption of Newer Diagnostic Modalities
  • Increasing Investments, Funds, and Grants By Public-Private Organizations

Restraints

  • High Cost of Diagnostic Imaging Systems
  • Short Half-Life of Radiopharmaceuticals
  • Limited Supply of Helium
  • Increasing Adoption of Refurbished Diagnostic Imaging Systems

Opportunities

  • Emerging Countries

Challenges

  • Hospital Budget Cuts

Companies Mentioned

  • Canon, Inc.
  • Curadel, LLC
  • Esaote SPA
  • Fluoptics
  • GE Healthcare
  • Hitachi, Ltd.
  • Impedimed Limited
  • Mindray Medical International Limited (A Subsidiary of Excelsior Union, Ltd.)
  • Mitaka Usa, Inc.
  • Neusoft Corporation
  • Philips
  • Shimadzu Corporation
  • Siemens Healthineers (A Subsidiary of Siemens Group)
  • Stryker Corporation
  • United Imaging Healthcare Co., Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/89jg28

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: BIOTECHNOLOGY HEALTH ONCOLOGY MEDICAL DEVICES

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 11/05/2019 06:29 AM/DISC: 11/05/2019 06:29 AM

Copyright Business Wire 2019.